AR125406A1 - Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen - Google Patents

Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen

Info

Publication number
AR125406A1
AR125406A1 ARP220101045A ARP220101045A AR125406A1 AR 125406 A1 AR125406 A1 AR 125406A1 AR P220101045 A ARP220101045 A AR P220101045A AR P220101045 A ARP220101045 A AR P220101045A AR 125406 A1 AR125406 A1 AR 125406A1
Authority
AR
Argentina
Prior art keywords
peptide
acid sequence
protein
gnpa
seq
Prior art date
Application number
ARP220101045A
Other languages
English (en)
Inventor
Joshua Joyner Sims
Yuan Yuan
James M Wilson
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of AR125406A1 publication Critical patent/AR125406A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan en el presente documento composiciones que incluyen péptidos de unión a los capilares cerebrales y/o que atraviesan la barrera hematoencefálica (BBB), vinculados a estos o insertos en una proteína selectiva de un vector recombinante que tiene al menos un péptido exógeno que comprende una secuencia de aminoácidos de Y-G/A/R/K-Y/H-GNPA-T/R/HRYFD-V/K. Se proporcionan composiciones que proporcionan dichos conjugados, péptidos selectivos o vectores recombinantes que tienen una cápside mutante o proteína de envoltura, así como usos de estos. Reivindicación 1: Una partícula de virus adenoasociado recombinante (rAAV) caracterizada porque comprende: (a) una cápside de AAV que comprende proteína VP1, proteínas VP2 y proteínas VP3, donde la proteína VP3 tiene una secuencia de aminoácidos que comprende una región hipervariable que comprende un péptido de direccionamiento exógeno que tiene la secuencia: conector de N-terminal opcional- Y-X’-X’’-GNPA-X’’’-RYFD-X’’’’, donde X’ es G, A, R, K, X’’ es Y o H, X’’’ es T, R o H, y X’’’’ es V o K (SEQ ID Nº 14) - conector de C-terminal opcional; y (b) un genoma vectorial empaquetado en la cápside de AAV, donde el genoma vectorial comprende una secuencia de ácidos nucleicos que codifica un producto génico bajo el control de secuencias que direccionan la expresión de este. Reivindicación 10: Un péptido de direccionamiento a células cerebrales recombinante, el péptido caracterizado porque comprende un motivo dirigido al núcleo de una secuencia de aminoácidos de Y-X’-X’’-GNPA-X’’’-RYFD-X’’’’, donde X’ es G, A, R, K, X’’ es Y o H, X’’’ es T, R o H, y X’’’’ es V o K (SEQ ID Nº 14), opcionalmente flanqueada en el amino terminal y/o en el carboxi terminal de la SEQ ID Nº 14 por dos aminoácidos a siete aminoácidos, y opcionalmente el péptido o péptido con conectores está conjugado con una nanopartícula, una segunda molécula o una proteína de cápside viral recombinante. Reivindicación 21: Un método para aumentar la transducción de células de producción de AAV in vitro caracterizado porque comprende transducir células con una secuencia de ácidos nucleicos que codifica una cápside de AAV que comprende un péptido de direccionamiento exógeno de Y-X’-X’’-GNPA-X’’’-RYFD-X’’’’, donde X’ es G, A, R, K, X’’ es Y o H, X’’’ es T, R o H, y X’’’’ es V o K (SEQ ID Nº 14) motivo del núcleo.
ARP220101045A 2021-04-23 2022-04-22 Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen AR125406A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163178881P 2021-04-23 2021-04-23

Publications (1)

Publication Number Publication Date
AR125406A1 true AR125406A1 (es) 2023-07-12

Family

ID=81585505

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101045A AR125406A1 (es) 2021-04-23 2022-04-22 Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen

Country Status (8)

Country Link
EP (1) EP4334334A1 (es)
AR (1) AR125406A1 (es)
AU (1) AU2022262771A1 (es)
BR (1) BR112023021971A2 (es)
CA (1) CA3216004A1 (es)
CO (1) CO2023014723A2 (es)
TW (1) TW202305124A (es)
WO (1) WO2022226263A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116693633B (zh) * 2023-02-21 2023-12-22 广州派真生物技术有限公司 腺相关病毒突变体及其应用

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08506144A (ja) 1993-02-05 1996-07-02 ラポート グループ オーストラリア リミティド スラグ脱泡複合材料
EP1978095A1 (en) 1993-02-12 2008-10-08 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptor proteins for controlling signal transduction and ligands binding thereto
US6140120A (en) 1993-02-12 2000-10-31 Board Of Trustees Of Leland Stanford Jr. University Regulated transcription of targeted genes and other biological events
US6972193B1 (en) 1993-02-12 2005-12-06 Board Of Trustees Of Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US20020173474A1 (en) 1993-02-12 2002-11-21 President And Fellows Of Harvard College Methods & materials involving dimerization-mediated regulation of biological events
US6150137A (en) 1994-05-27 2000-11-21 Ariad Pharmaceuticals, Inc. Immunosuppressant target proteins
US6476200B1 (en) 1994-06-27 2002-11-05 The Johns Hopkins University Mammalian proteins that bind to FKBP12 in a rapamycin-dependent fashion
US6492106B1 (en) 1994-06-27 2002-12-10 The Johns Hopkins University Mammalian proteins that bind to FKBP12 in a rapamycin-dependent fashion
US6133456A (en) 1994-08-18 2000-10-17 Ariad Gene Therapeutics, Inc. Synthetic multimerizing agents
ATE299145T1 (de) 1994-08-18 2005-07-15 Ariad Gene Therapeutics Inc Neues multimerisierendes reagenz
US6150527A (en) 1994-08-18 2000-11-21 Ariad Pharmaceuticals, Inc. Synthetic multimerizing agents
US6326166B1 (en) 1995-12-29 2001-12-04 Massachusetts Institute Of Technology Chimeric DNA-binding proteins
AU719001B2 (en) 1994-12-29 2000-05-04 Massachusetts Institute Of Technology Chimeric DNA-binding proteins
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
US6506379B1 (en) 1995-06-07 2003-01-14 Ariad Gene Therapeutics, Inc. Intramuscular delivery of recombinant AAV
CA2219080A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamycin-based regulation of biological events
AU731826B2 (en) 1996-02-28 2001-04-05 Ariad Pharmaceuticals, Inc. Synthetic Multimerizing Agents
US6723531B2 (en) 1996-04-05 2004-04-20 The Salk Institute For Biological Studies Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US6479653B1 (en) 1997-08-26 2002-11-12 Ariad Gene Therapeutics, Inc. Compositions and method for regulation of transcription
US6015709A (en) 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
EP1017829A2 (en) 1997-08-26 2000-07-12 Ariad Gene Therapeutics, Inc. Fusion proteins comprising a dimerization, trimerization or tetramerization domain and an additional heterologous transcription activation, transcription repression, dna binding or ligand binding domain
EP1003886A1 (en) 1997-08-27 2000-05-31 Ariad Gene Therapeutics, Inc. Chimeric transcriptional activators and compositions and uses related thereto
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
JP2002508971A (ja) 1998-01-15 2002-03-26 アリアド・ジーン・セラピューティクス・インコーポレーテッド 多量体キメラ蛋白質を使用する生物学的イベントの調節
US6984635B1 (en) 1998-02-13 2006-01-10 Board Of Trustees Of The Leland Stanford Jr. University Dimerizing agents, their production and use
EP1053241A1 (en) 1998-02-13 2000-11-22 President And Fellows Of Harvard College Novel dimerizing agents, their production and use
US6333318B1 (en) 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
US6258603B1 (en) 1998-06-17 2001-07-10 Rohm And Haas Company Ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7109317B1 (en) 1998-11-06 2006-09-19 President And Fellows Of Harvard College FK506-based regulation of biological events
ATE403715T1 (de) 1999-08-09 2008-08-15 Targeted Genetics Corp Erhöhung der expression einer einzelsträngigen, heterologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
WO2001014387A1 (en) 1999-08-24 2001-03-01 Ariad Gene Therapeutics, Inc. 28-epirapalogs
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
CA2404253C (en) 2000-03-22 2014-05-13 Rohm And Haas Company Novel ecdysone receptor-based inducible gene expression system
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
US9493540B2 (en) 2001-02-20 2016-11-15 Intrexon Corporation Ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system
US8715959B2 (en) 2001-02-20 2014-05-06 Intrexon Corporation Substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
JP4955905B2 (ja) 2001-02-20 2012-06-20 イントレキソン コーポレーション キメラレチノイドｘ受容体および新規エクジソン受容体−ベースの誘導性遺伝子発現システムにおけるそれらの使用
US9249207B2 (en) 2001-02-20 2016-02-02 Intrexon Corporation Substitution mutant receptors and their use in an ecdysone receptor-based inducible gene expression system
DK1310571T3 (da) 2001-11-13 2006-06-19 Univ Pennsylvania Fremgangsmåde til identifikation af ukendte adeno-associerede virussekvenser (AAV-sekvenser) og et kit til fremgangsmåden
EP1453547B1 (en) 2001-12-17 2016-09-21 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor
ES2411479T3 (es) 2003-09-30 2013-07-05 The Trustees Of The University Of Pennsylvania Clados de virus adeno-asociados (AAV), secuencias, vectores que los contienen, y usos de los mismos
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
EP3085389A1 (en) 2005-04-07 2016-10-26 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
EP1777906A1 (en) 2005-06-09 2007-04-25 Matsushita Electric Industrial Co., Ltd. Amplitude error compensating apparatus and orthogonality error compensating apparatus
EP2007795B1 (en) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
US8969353B2 (en) 2008-11-07 2015-03-03 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
JP5922095B2 (ja) 2010-03-29 2016-05-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 薬理学的に誘導される導入遺伝子アブレーション系
US20130037977A1 (en) 2010-04-08 2013-02-14 Paul A. Burke Preparation of Lipid Nanoparticles
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US8853377B2 (en) 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
US20140031418A1 (en) 2011-04-20 2014-01-30 The Trustees Of The University Of Pennsylvania Regimens and Compositions for AAV-Mediated Passive Immunization of Airborne Pathogens
CN104160033B (zh) 2011-05-27 2018-06-01 阿米库斯治疗学公司 将靶向肽偶联于重组溶酶体酶上的方法
IL280771B2 (en) 2011-06-08 2024-03-01 Shire Human Genetic Therapies Preparations of lipid nanoparticles and methods for administration of mRNA
FR2977562B1 (fr) 2011-07-06 2016-12-23 Gaztransport Et Technigaz Cuve etanche et thermiquement isolante integree dans une structure porteuse
EP3800254A1 (en) 2012-06-08 2021-04-07 Ethris GmbH Pulmonary delivery of messenger rna
EP2929035A1 (en) 2012-12-07 2015-10-14 Shire Human Genetic Therapies, Inc. Lipidic nanoparticles for mrna delivering
EP3714893A1 (en) 2013-03-15 2020-09-30 Amicus Therapeutics, Inc. Chemical crosslinkers
EP4324480A3 (en) * 2013-05-20 2024-05-08 F. Hoffmann-La Roche AG Anti-transferrin receptor antibodies and methods of use
CN105873902B (zh) 2013-11-18 2019-03-08 阿克丘勒斯治疗公司 用于rna递送的可电离的阳离子脂质
CA2946392A1 (en) 2014-04-25 2015-10-29 James M. Wilson Ldlr variants and their use in compositions for reducing cholesterol levels
BR112017005892A2 (pt) 2014-09-24 2017-12-12 Hope City variantes de vetor de vírus adeno-associado para edição de genoma de alta eficácia e métodos da mesma
EA201792500A1 (ru) 2015-05-13 2018-04-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Aav-опосредованная экспрессия антител против гриппа и способы их использования
ES2869284T3 (es) 2015-12-11 2021-10-25 California Inst Of Techn Péptidos de diana para dirigir virus adenoasociados (AAV)
SG10201912976WA (en) 2017-02-28 2020-02-27 Univ Pennsylvania Adeno-associated virus (aav) clade f vector and uses therefor
SG10201913833PA (en) 2017-02-28 2020-03-30 Univ Pennsylvania Influenza vaccines based on aav vectors
WO2019168961A1 (en) 2018-02-27 2019-09-06 The Trustees Of The University Of Pennsylvania Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
BR112021011143A2 (pt) 2018-12-21 2022-01-25 Univ Pennsylvania Composições para redução específica de drg da expressão de transgene
US11867060B2 (en) 2019-02-04 2024-01-09 Technische Universität Wien Reinforced concrete tubbing segment
EP3976077A4 (en) 2019-04-29 2023-08-30 The Trustees of The University of Pennsylvania NOVEL AAV CAPSIDS AND COMPOSITIONS CONTAINING THEM
EP4045637A4 (en) * 2019-10-16 2023-11-22 The Broad Institute, Inc. TECHNICAL COMPOSITIONS FOR MUSCLE BUILDING
US20230304034A1 (en) 2020-05-12 2023-09-28 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
CA3183153A1 (en) 2020-06-17 2021-12-23 Christian HINDERER Compositions and methods for treatment of gene therapy patients
JP2023537625A (ja) 2020-08-14 2023-09-04 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規ａａｖカプシド及びそれを含む組成物

Also Published As

Publication number Publication date
CA3216004A1 (en) 2022-10-27
AU2022262771A1 (en) 2023-11-02
AU2022262771A9 (en) 2023-11-16
BR112023021971A2 (pt) 2024-02-20
CO2023014723A2 (es) 2023-11-20
TW202305124A (zh) 2023-02-01
EP4334334A1 (en) 2024-03-13
WO2022226263A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
RU2020113681A (ru) Капсиды вариантов аденоассоциированных вирусов и методы их применения
CN114127089A (zh) 重组腺相关病毒及其用途
CN112703198A (zh) 用于跨血脑屏障递送试剂的方法和组合物
JP2020510429A5 (es)
FI3445773T3 (fi) Adenoassosioituneen viruksen kapsidimuunnoksia ja niiden käyttömenetelmiä
WO2012172277A4 (en) Simian adenovirus and hybrid adenoviral vectors
JP2022531095A (ja) エキソソーム及びａａｖの組成物
JP2022551487A (ja) 改変されたａａｖカプシドおよびその使用
JP2021514659A (ja) Ａａｖキメラ
CN112041451B (zh) 基于aav的基因和蛋白质递送模块化***
AR125406A1 (es) Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen
CA3173450A1 (en) High throughput engineering of functional aav capsids
CA3216419A1 (en) Tissue-targeted modified aav capsids and methods of use thereof
WO2022232327A9 (en) Aav capsids and uses thereof
JP2021533821A (ja) 組換え核酸コンストラクト
AR124216A1 (es) Composiciones nuevas con motivos selectivos específicos del tejido y composiciones que las contienen
KR20220117914A (ko) 신규 세포 전달 방법
CA3202675A1 (en) Viral capsid proteins with specificity to heart tissue cells
ES2273277T3 (es) Peptidos moduladores de la actividad del factor de transcripcion engrailed.
US20120190107A1 (en) Enhanced protein transduction
US20230175013A1 (en) Controlled modification of adeno-associated virus (aav) for enhanced gene therapy
WO2024017387A1 (en) Novel aav capsids for targeting nervous system and uses thereof
WO2020187268A1 (zh) 一种增强基因编辑的融合蛋白及其应用
KR20170033559A (ko) 유전자 전달을 위한 신규의 융합 펩타이드
Tasfaout et al. Split intein-mediated protein trans-splicing to express large dystrophins